FDA stinks at policing conflicts

Just when you thought nobody could be worse than the National Institutes of Health at managing financial conflicts of interest among trial investigators... The Inspector General of the Department of Health and Human Services released a linkurl:report;http://www.oig.hhs.gov/oei/reports/oei-05-07-00730.pdf today that indicates a pretty severe lack of oversight over at the Food and Drug Administration. The report found that only one percent of the almost 27,000 clinical investigators contracted by

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Just when you thought nobody could be worse than the National Institutes of Health at managing financial conflicts of interest among trial investigators... The Inspector General of the Department of Health and Human Services released a linkurl:report;http://www.oig.hhs.gov/oei/reports/oei-05-07-00730.pdf today that indicates a pretty severe lack of oversight over at the Food and Drug Administration. The report found that only one percent of the almost 27,000 clinical investigators contracted by the agency in 2007 disclosed a financial interest. In 42% of clinical trials, the FDA never even received the financial disclosure forms from participating investigators that the agency mandates. The FDA not only failed to address these shortcomings, in 20% of the trials where investigators did report a financial conflict, the FDA took no action. In 31% of trials where researchers did submit financial conflict documentation, FDA reviewers didn't even indicate that they read the forms. If this isn't enough to make you smack your forehead and send your morning coffee spraying from one nostril, the FDA also apparently told the inspector general that it wasn't that interested in requiring drug makers to collect and report accurate financial disclosure information from investigators prior to the commencement of clinical trials. "FDA asserted that this additional effort would not be worthwhile because financial interests are only one form of potential bias," the report reads. All of this doesn't appear to be bothering potential clinical trial participants searching to wring a buck out of our foundering economy, though. The __Boston Globe__ linkurl:reported;http://www.boston.com/news/world/europe/articles/2009/01/05/paid_studies_draw_more_interest_in_sour_economy/?page=1 last week that the number of Americans seeking to become paid clinical trial subjects has skyrocketed since the economy went south.
**__Related stories:__***linkurl:Should conflicts mean no NIH grant?;http://www.the-scientist.com/blog/display/55058/
[29th September 2008]*linkurl:Report faults NIH on conflicts;http://www.the-scientist.com/blog/display/54183/
[18th January 2008]*linkurl:CSPI: FDA can manage conflicts better;http://www.the-scientist.com/blog/display/53953/
[3rd December 2007]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Skip the Wait for Protein Stability Data with Aunty

Skip the Wait for Protein Stability Data with Aunty

Unchained Labs

Products

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform

nuclera logo

Nuclera eProtein Discovery System installed at leading Universities in Taiwan

Brandtech Logo

BRANDTECH Scientific Introduces the Transferpette® pro Micropipette: A New Twist on Comfort and Control